Milstein Award Lecture: Interferons and cancer: Where from here?

被引：36

作者：

Borden, EC ^{[1
]}

机构：

[1] Lerner Res Inst, Taussig Canc Ctr, Ctr Hematol & Oncol Mol Therapeut, Cleveland, OH 44195 USA

来源：

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH | 2005年 / 25卷 / 09期

关键词：

D O I：

10.1089/jir.2005.25.511

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interferons ( IFNs) remain the most broadly active cytokines for cancer treatment, yet ones for which the full potential is not reached. IFNs have impacted positively on both quality and quantity of life for hundreds of thousands of cancer patients with chronic leukemia, lymphoma, bladder carcinoma, melanoma, and renal carcinoma. The role of the IFN system in malignant pathogenesis continues to enhance understanding of how the IFN system may be modulated for therapeutic advantage. Reaching the full potential of IFNs as therapeutics for cancer will also result from additional understanding of the genes underlying apoptosis induction, angiogenesis inhibition, and influence on immunologic function. Food and Drug Administration ( FDA) approval of IFNs occurred less than 20 years ago; after 40 years, third- generation products of early cytotoxics, such as 5-fluorouracil ( 5FU), are beginning to reach clinical approval. Thus, substantial potential exists for additional application of IFNs and IFN inducers as anticancer therapeutics, particularly when one considers that their pleiotropic cellular and molecular effects have yet to be fully defined.

引用

页码：511 / 527

页数：17

共 216 条

[91]

Johnsen A, 1998, CANCER RES, V58, P3660

[92] Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a [J].

Kaban, LB ;

Mulliken, JB ;

Ezekowitz, RA ;

Ebb, D ;

Smith, PS ;

Folkman, J .

PEDIATRICS, 1999, 103 (06) :1145-1149

[93] Natural interferon α/β-producing cells link innate and adaptive immunity [J].

Kadowaki, N ;

Antonenko, S ;

Lau, JYN ;

Liu, YJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (02) :219-225

[94] In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents [J].

Kano, Y ;

Akutsu, M ;

Tsunoda, S ;

Mano, H ;

Sato, Y ;

Honma, Y ;

Furukawa, Y .

BLOOD, 2001, 97 (07) :1999-2007

[95] Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice [J].

Kaplan, DH ;

Shankaran, V ;

Dighe, AS ;

Stockert, E ;

Aguet, M ;

Old, LJ ;

Schreiber, RD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) :7556-7561

[96] Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells [J].

Karpf, AR ;

Peterson, PW ;

Rawlins, JT ;

Dalley, BK ;

Yang, Q ;

Albertsen, H ;

Jones, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :14007-14012

[97] Hypermethylation of the DAP-Kinase CpG island is a common alteration in B-cell malignancies [J].

Katzenellenbogen, RA ;

Baylin, SB ;

Herman, JG .

BLOOD, 1999, 93 (12) :4347-4353

[98] Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type IIFNs [J].

Kayagaki, N ;

Yamaguchi, N ;

Nakayama, M ;

Eto, H ;

Okumura, K ;

Yagita, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (09) :1451-1460

[99] High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190 [J].

Kirkwood, JM ;

Ibrahim, JG ;

Sondak, VK ;

Richards, J ;

Flaherty, LE ;

Ernstoff, MS ;

Smith, TJ ;

Rao, U ;

Steele, M ;

Blum, RH .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2444-2458

[100] INVIVO BIOLOGICAL RESPONSE TO RECOMBINANT INTERFERON-GAMMA DURING A PHASE-I DOSE-RESPONSE TRIAL IN PATIENTS WITH METASTATIC MELANOMA [J].

KIRKWOOD, JM ;

ERNSTOFF, MS ;

TRAUTMAN, T ;

HEBERT, G ;

NISHIDA, Y ;

DAVIS, CA ;

BALZER, J ;

REICH, S ;

SCHINDLER, J ;

RUDNICK, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :1070-1082

← 5 6 7 8 9 10 11 12 13 14 →